Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00693186 | A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA | PHASE3 | COMPLETED | 410 | — | — | Oct 1, 2008 | Mar 1, 2010 | Sep 11, 2017 | 5 | Italy |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HBVaxPRO® 5 µg / 0.5 mL | BIOLOGICAL | 5 µg / 0.5 mL |
| Engerix B® 10 µg / 0.5 mL | BIOLOGICAL | 10 µg |
Inclusion Criteria: * Healthy child of 4 to 7 years of age of either gender, * Child vaccinated with 2 doses of HEXAVAC® during the first 6 months of life and with a 3rd dose of HEXAVAC® before the end of the second year of life or Child vaccinated with 2 doses of INFANRIX®-HEXA during the first 6 ...